GLOW

GLOW is a three-peptide research blend: 50MG GHK-Cu, 10MG BPC-157 and 10MG TB-500, 70MG in total. GHK-Cu is a copper-binding tripeptide, BPC-157 is a synthetic 15-residue peptide, and TB-500 is a name tied to thymosin beta-4. No published study has tested the three together, so this guide keeps each finding with the component tested, names its model and links each component's full guide.

The vial page lists TB-500 by that name only; the pen page lists BPC-157, "TB-500 / Thymosin Beta-4 Fragment" and GHK-Cu at 10MG / 10MG / 50MG. Formulas, weights and CIDs are from PubChem.

Each summary covers studies that tested one component alone. None used GLOW, and no finding transfers to the other components or to the mixture.

GHK-Cu

GHK (glycyl-L-histidyl-L-lysine) was isolated from human plasma (Maquart et al., 1988). During its isolation it co-purified with roughly equimolar copper, and the tripeptide readily formed complexes with copper(II) and increased copper uptake into cultured hepatoma cells (Pickart et al., 1980). Its copper(II) complex is dimeric in the crystal and monomeric in solution, where copper is held by the N-terminal amine, a backbone amide nitrogen and the histidine imidazole (Hureau et al., 2011).

In fibroblast cultures, GHK-Cu stimulated collagen synthesis beginning between 10⁻¹² and 10⁻¹¹ M and peaking at 10⁻⁹ M, independent of cell number (Maquart et al., 1988). In lipopolysaccharide-stimulated RAW 264.7 mouse macrophages it lowered reactive oxygen species, and in those cells and in mice with lipopolysaccharide-induced acute lung injury it lowered TNF-α and IL-6 and suppressed NF-κB p65 and p38 MAPK signaling (Park et al., 2016). More is in the GHK-Cu research guide.

BPC-157

BPC-157 is a 15-amino-acid partial sequence of body protection compound, which was isolated from human gastric juice (Chang et al., 2011). In rat gastric mucosa homogenates, BPC-157 at 100 µM generated nitric oxide at a level comparable to the precursor L-arginine, and the nitric oxide synthase inhibitor L-NAME did not inhibit it; the same rat study examined ethanol-induced gastric lesions (Sikirić et al., 1997).

In isolated rat aorta it produced endothelium-dependent vasodilation that L-NAME or hemoglobin inhibited, and in human umbilical vein endothelial cells it raised phosphorylation of Src, caveolin-1 and eNOS (Hsieh et al., 2020). In rat tendon explants and cultured tendon fibroblasts, it increased explant outgrowth, fibroblast survival under hydrogen peroxide stress and fibroblast migration, with higher FAK and paxillin phosphorylation (Chang et al., 2011).

A 2025 systematic review that searched PubMed, Cochrane and Embase through June 2024 included 36 studies, 35 preclinical and one clinical (Vasireddi et al., 2025). The BPC-157 research guide covers it in full.

TB-500

TB-500 needs care, because the fragment and the full protein are different molecules. A doping-control laboratory identified Ac-LKKTETQ, the acetylated 17 to 23 fragment of human thymosin beta-4, in a TB-500 product by high-resolution mass spectrometry and also synthesized it (Esposito et al., 2012). A racing laboratory described TB-500 as a veterinary preparation whose key ingredient is LKKTETQ with an artificially acetylated N-terminus, the thymosin beta-4 segment responsible for actin binding, and detected it in horse urine and plasma (Ho et al., 2012).

Full-length thymosin beta-4 is a 43-amino-acid, 5 kDa polypeptide regarded as the main G-actin sequestering peptide; in human umbilical vein endothelial cell migration and chick aortic arch sprouting assays, the full protein and its seven-residue actin-binding motif showed near-identical activity at about 50 nM (Philp et al., 2003).

A 2024 study notes that such functions were reported for unacetylated LKKTETQ and that biological effects of acetylated TB-500 had not been documented; in its own fibroblast assays only the metabolite Ac-LKKTE, not TB-500, differed significantly from control, and in rat urine the main metabolite over the first six hours was Ac-LK (Rahaman et al., 2024). Findings for the full protein should not be assumed to carry over to the fragment. The TB-500 research guide keeps the two apart.

No published study has tested GLOW, or GHK-Cu, BPC-157 and TB-500 together, in any model. A PubMed search on 14 October 2026 for records naming all three in the title or abstract (GHK-Cu, GHK, copper tripeptide, copper peptide or Gly-His-Lys; BPC-157, pentadecapeptide or body protection compound; TB-500, thymosin beta-4 or LKKTETQ; with spelling variants and codes) returned six records, all reviews, and pairing GLOW with any of the three names returned none. No published study reports how the three interact, how stable the mixture is in a vial or in solution, or any combined effect.

The same search run for each pair of components found one controlled experiment that combined two of them. In it, 32 male Sprague-Dawley rats underwent a standardized surgical Achilles tendon transection and were randomly assigned to control, BPC-157, TB-500 (described in the abstract as synthetic thymosin beta-4) or both, for four weeks.

Maximum load to failure was higher than control in the BPC-157 and TB-500 groups, significantly so only for TB-500, and the combination showed no additive effect over either peptide alone (Biçer et al., 2026). It is one exploratory rat study, without GHK-Cu. Studies using GLOW should handle it as a defined mixture, with a control for each component.

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (Brzoska et al., 2008). GLOW is therefore KLOW without KPV, a KPV-free comparator. The GLOW vs KLOW comparison sets the two side by side.